Category
decision framework
Structured ways to think through whether, when, and how a peptide makes sense — the trade-offs, the safety questions, and the honest unknowns.
decision-framework
FDA uses AI to flag peptide vendors labeled ‘research use only’
Ian Gauntt, RN BSN · Sep 18, 2026 · 3 min
FDA deploys AI surveillance to flag peptide vendors whose “research use only” labels mask human‑use claims, prompting warning letters and enforcement actions.
decision-framework
Emideltide (DSIP) Falls Short in FDA Compounding Vote
Ian Gauntt, RN BSN · Sep 15, 2026 · 2 min
FDA advisory panel rejected emideltide (DSIP) from the 503A compounding list citing safety, route mismatch, and poor characterization. Highlights evidence thresholds.
decision-framework
Peptide fertility strategies: what research shows
Ian Gauntt, RN BSN · Sep 12, 2026 · 13 min
Peptide fertility strategies are emerging to counter TRT-induced suppression. Here's what a 2025 narrative review found in preclinical and clinical data.
decision-framework
BMJ flags peptide safety and conflict concerns
Ian Gauntt, RN BSN · Sep 12, 2026 · 2 min
BMJ reports FDA scientists worry about carcinogenicity, organ toxicity, addiction risks in experimental peptides, and advisory panel industry ties that may skew regulation.
decision-framework
Cagrisema Weight Loss: What RCT Data Show
Ian Gauntt, RN BSN · Aug 31, 2026 · 13 min
A 2025 meta-analysis pooled RCT data on cagrisema weight loss. Here is what the evidence found and what remains uncertain.
decision-framework
Real-World Drug Data: What Studies Actually Show
Ian Gauntt, RN BSN · Aug 24, 2026 · 14 min
Real-world drug data from five 2025 studies reveals how semaglutide, lecanemab, and upadacitinib perform outside controlled trials—and what the gaps mean.
decision-framework
GLP-1 Agonists: What New Research Shows
Ian Gauntt, RN BSN · Aug 22, 2026 · 14 min
GLP-1 agonists are showing up in surprising clinical contexts. Here's what new research shows about epilepsy, stoma care, and heart signals.
decision-framework
GLP-1 Agonists: What Epilepsy Research Shows
Ian Gauntt, RN BSN · Aug 17, 2026 · 15 min
GLP-1 agonists meet epilepsy: what a 2025 clinical study found about safety and efficacy in adults with obesity, type 2 diabetes, and seizure disorders.
decision-framework
GLP-1 Analogues: What High-Output Stoma Research Shows
Ian Gauntt, RN BSN · Aug 15, 2026 · 11 min
GLP-1 analogues are being studied for high-output stomas. Here's what a 2025 narrative review found about mechanisms, evidence, and open questions.
decision-framework
GLP-1 Analogues: What Research Shows for High-Output Stoma
Ian Gauntt, RN BSN · Aug 10, 2026 · 12 min
GLP-1 analogues are being studied for high-output stoma management. Here's what the latest narrative review evidence actually shows.
decision-framework
Decision Frameworks: Reading New Drug Data
Ian Gauntt, RN BSN · Aug 8, 2026 · 13 min
Learn decision frameworks for reading new drug data across cancer, metabolic, and neurological research—without falling for hype or missing real signals.
decision-framework
Decision Frameworks: Reading New Drug Data
Ian Gauntt, RN BSN · Aug 3, 2026 · 16 min
Decision frameworks help you understand what recent clinical trials on peptides and drugs actually found—and what the evidence really means for research.
decision-framework
Treatment Trade-offs: How to Weigh Your Options
Ian Gauntt, RN BSN · Aug 1, 2026 · 15 min
Explore treatment trade-offs across six therapy areas—from Cushing's syndrome to migraine—using real study findings to guide smarter conversations with your doctor.
decision-framework
Treatment Trade-offs: How to Weigh New Data
Ian Gauntt, RN BSN · Jul 27, 2026 · 15 min
Treatment trade-offs explained: what recent clinical studies reveal about efficacy, safety, and decision frameworks for emerging therapies.
decision-framework
Should You Use Peptides? A Decision Framework
Ian Gauntt, RN BSN · Jul 13, 2026 · 2 min
Skip the hype. A structured framework for evaluating whether a given peptide makes sense — evidence tier, sourcing, regulatory status, and risk.